Datopotamab Deruxtecan vs Docetaxel用于既往治疗的晚期或转移性NSCLC

文章预览

SCI 2 October 2024 Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study  (JCO, IF: 42.1) Ahn M-J, Tanaka K, Paz-Ares L, et al: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol JCO2401544, 2024 Purpose 目的 The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC). 这项随机、开放标签、全球 III 期 TROPION-Lung01研究比较了Datopotamab Deruxtecan (Dato-DXd) vs Docetaxel（多西紫杉醇）用于既往治疗的晚期/转移性非小细胞肺癌(NSCLC)患者的疗效和安全性。 Methods 方法 Patients received Dato-DXd 6 mg/kg or docetax ………………………………